| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Cyclo(Gly-Gln) is capable of reversing the cardiorespiratory depression produced by β-endorphin or morphine. It may target opioid receptors or downstream signaling pathways. It exhibits various biological activities, including antioxidant properties and the ability to modulate cellular signaling pathways.
|
|---|---|
| ln Vitro |
In vitro, Cyclo(Gly-Gln) is a biologically active peptide. It shows promising activity against certain diseases, particularly in the research of cancer, neurodegenerative disorders, and metabolic diseases. It has antioxidant properties and can modulate cellular signaling pathways.
|
| ln Vivo |
In vivo, Cyclo(Gly-Gln) is capable of reversing the cardiorespiratory depression produced by β-endorphin or morphine. It has potential applications in cancer, neurodegenerative disorders, and metabolic diseases. Animal studies are needed to further confirm its efficacy.
|
| Enzyme Assay |
Cell-free assays for Cyclo(Gly-Gln): opioid receptor binding is assessed using radioligand binding assays with membrane preparations. The compound is incubated with receptor membranes and radiolabeled ligands, and specific binding is measured by scintillation counting. Antioxidant activity is measured using DPPH and ABTS assays.
|
| Cell Assay |
Cellular assays for Cyclo(Gly-Gln): cells (e.g., neuronal cells, cancer cell lines) are cultured and treated with Cyclo(Gly-Gln) at concentrations of 0.1-100 µM for 24-72 hours. Cell viability is measured by MTT assay. Apoptosis is assessed by Annexin V/PI staining. ROS levels are measured using DCFH-DA. Signaling pathways are assessed by Western blot.
|
| Animal Protocol |
In vivo animal studies for Cyclo(Gly-Gln): animal models of cardiorespiratory depression (e.g., morphine-treated animals), cancer, or neurodegenerative diseases would be used. Animals are administered Cyclo(Gly-Gln) orally or intraperitoneally at doses of 1-10 mg/kg. Cardiorespiratory parameters, tumor growth, and neurological function are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Cyclo(Gly-Gln): as a small cyclic peptide (molecular weight 185.18), it may have moderate oral bioavailability. It is likely metabolized in the liver and excreted via the kidneys. Storage: powder at -20°C for up to 3 years.
|
| Toxicity/Toxicokinetics |
Toxicity of Cyclo(Gly-Gln): comprehensive toxicity data are limited. As a cyclic dipeptide, it is generally considered safe at moderate doses. It is for research use only and not approved for clinical use.
|
| References | |
| Additional Infomation |
Cyclo(Gly-Gln) is a research compound with potential applications in cancer, neurodegenerative disorders, metabolic diseases, and opioid-induced respiratory depression research. It is a biologically active cyclic dipeptide. No clinical trials or FDA approvals have been reported.
|
| Molecular Formula |
C7H11N3O3
|
|---|---|
| Molecular Weight |
185.18
|
| Exact Mass |
185.08
|
| CAS # |
52662-00-7
|
| PubChem CID |
7408479
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
722.0±45.0 °C at 760 mmHg
|
| Flash Point |
390.5±28.7 °C
|
| Vapour Pressure |
0.0±2.3 mmHg at 25°C
|
| Index of Refraction |
1.498
|
| LogP |
-3.46
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
13
|
| Complexity |
251
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1C(=O)N[C@H](C(=O)N1)CCC(=O)N
|
| InChi Key |
PWADXPITHGKDSY-BYPYZUCNSA-N
|
| InChi Code |
InChI=1S/C7H11N3O3/c8-5(11)2-1-4-7(13)9-3-6(12)10-4/h4H,1-3H2,(H2,8,11)(H,9,13)(H,10,12)/t4-/m0/s1
|
| Chemical Name |
3-[(2S)-3,6-dioxopiperazin-2-yl]propanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 13.89 mg/mL (75.01 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.4002 mL | 27.0008 mL | 54.0015 mL | |
| 5 mM | 1.0800 mL | 5.4002 mL | 10.8003 mL | |
| 10 mM | 0.5400 mL | 2.7001 mL | 5.4002 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
